rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Treatment landscape of targeted therapies in oncology
    sub title: challenges and opportunities
  name:
    name part: Maurya, Pawan Kumar
    role:
      role term: editor.
  name:
    name part: Saini, Vikas
    role:
      role term: editor.
  name:
    name part: ScienceDirect (Online service)
  type of resource: text
  genre: bibliography
  genre: Electronic books.
  origin info:
    place:
      place term: enk
    date issued: 2023
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: remote
    extent: 1 online resource (xviii, 251 pages) : illustrations (some color)
  abstract: Treatment Landscape of Targeted Therapies in Oncology: Challenges and Opportunities provides up-to-date knowledge on antitumor-targeted therapies and immunotherapy. The book's chapters are written by researchers dynamically working/focusing on cancer treatment. The content is designed to help those who are new to the field (beginners) and various specialized scientists and researchers involved in cancer research. For decades, the hallmark of cancer treatment has been conventional chemotherapy. But with the rapid increase in our understanding of the immune system, more and more small molecules, peptides, recombinant antibodies, vaccines and cellular therapeutic modalities are being applied to manipulate the immune response for cancer treatment.
  table of contents: Intro -- Title page -- Table of Contents -- Copyright -- List of contributors -- Preface -- Chapter 1. Biology of cancer: current insights and perspectives -- Abstract -- Introduction -- A perspective on cancer cell -- Epidemiology of cancer -- Clinical features and diagnosis -- Current and emerging treatment strategies -- Modern challenges in cancer therapy -- Emerging/advanced treatment strategies -- Conclusion and future perspectives -- References -- Chapter 2. Evolution of targeted therapies in cancer: opportunities and challenges -- Abstract -- Introduction -- Types of cancer -- Lung cancer -- Breast cancer -- Colorectal cancer -- Brain cancer -- Blood cancer -- Skin cancer -- Cervical cancer -- Targeted therapies in cancer -- Monoclonal antibodies -- Small molecule inhibitors -- Targeted immunotherapy -- Nanomaterials in cancer therapy -- Opportunities and challenges of targeted cancer therapy -- Conclusions -- Acknowledgments -- Conflict of interest -- Glossary words -- Essay type questions -- References -- Chapter 3. Clinical implementation of biomarkers and signaling pathway as novel targeted therapeutics in breast cancer -- Abstract -- Background -- Factors affecting breast cancer -- Classification of breast cancer -- Biomarkers in breast cancer: diagnostic to targeted therapy -- Targeting molecular signaling pathways -- HER2-positive targeted therapies -- HER2-negative targeted therapies -- Targeted therapy as emerging treatment options -- Conclusion and future perspective -- References -- Chapter 4. Targeted therapies in advanced lung cancerâ€"current landscapes and future projects -- Abstract -- Introduction -- What are targeted therapies -- Large molecule inhibitors -- Immunotherapy -- Monoclonal antibodies -- Small molecule inhibitors and their targets -- Conclusion and future perspectives -- Acknowledgment -- References.
  table of contents: Chapter 5. Targeted therapies: emerging biomarkers in advanced melanoma -- Abstract -- Introduction -- Biomarkers in melanoma (prognostic and predictive) -- Malignant melanoma classification, diagnosis and treatment -- Nanotechnology: mechanisms and nanoparticles in melanoma therapies -- Nanosystems for improved targeted therapies in melanoma -- Conclusion -- References -- Chapter 6. Targeting immune checkpoints for cancer therapy -- Abstract -- Introduction -- Immune checkpoints -- Cytotoxic T-lymphocyte-associated antigen-4 signaling pathway: a promising therapeutic target in cancer -- Anti-PD-1/PDL-1 therapy -- Targeting mammalian target of rapamycin pathway for cancer therapy -- Vascular endothelial growth factor pathway in cancer therapy -- Targeting PI3k/Akt pathway -- Targeting mitogen-activated protein kinases network for cancer prevention -- Inhibition of cyclin-dependent kinases for cancer therapy -- Inhibiting epidermal growth factor receptor and human epidermal growth factor receptor 2 for cancer therapy -- Conclusion -- References -- Chapter 7. Glioblastoma targeted therapies: updated approaches from recent biological insights -- Abstract -- Abbreviations -- Introduction -- Various therapies for glioblastoma multiforme -- Conclusion -- References -- Chapter 8. Current trends and future prospects of molecular targeted therapy in head and neck squamous carcinoma -- Abstract -- Abbreviations -- Introduction -- Epidemiology -- Symptoms and pathophysiology -- Diagnosis and prevention -- Therapeutic strategies -- Existing therapies -- Future prospects -- Summary -- References -- Chapter 9. Targeted therapy and drug resistance in gastric and pancreatic cancer -- Abstract -- Targeted therapy and drug resistance in gastric cancer -- Targeted therapy and drug resistance in pancreatic cancer -- References.
  table of contents: Chapter 10. Colorectal cancer heterogeneity and targeted therapy: clinical implications, challenges, and solutions for treatment resistance -- Abstract -- Introduction -- Molecular biology in metastatic colorectal cancer -- Systemic therapy in metastatic colorectal cancer -- Chemotherapy backbone for metastatic colorectal cancer -- Targeted therapy in first-line setting metastatic colorectal cancer -- Anti-VEGF: bevacizumab -- Antiepidermal growth factor receptor: cetuximab, panitumumab -- Immunotherapy -- BRAF-mutated -- KRAS-G12C-mutation in mCRC -- Elderly/frail patients -- Treatment alternatives after first-line -- Anti-VEGF -- Antiepidermal growth factor receptor -- Anti-BRAF+antiepidermal growth factor receptor -- Treatment alternatives in later lines -- Tyrosine kinase inhibitors -- Thymidine-based nucleoside analogs -- Immunotherapy -- Human epidermal growth factor receptor r2-directed therapy -- Rare actionable fusion proteins -- Local ablative therapy -- Conclusion -- References -- Chapter 11. Endometrial cancer: molecular markers and management of advanced-stage disease -- Abstract -- Introduction -- Type 1 versus type 2 -- Classification of endometrial cancer on molecular basis -- Molecular markers of endometrial cancer -- Management of endometrial cancer -- Risk factors for endometrial cancer -- Conclusion -- Acknowledgments -- Statements and declaration -- Glossary items -- Essay-type questions -- References -- Index.
  note: edited by Pawan Kumar Maurya, Vikas Saini.
  note: Includes bibliographical references and index.
  subject:
    topic: Cancer
    topic: Treatment
    topic: Technological innovations
  subject:
    topic: Immunotherapy
  subject:
    topic: Cancer
    topic: Immunotherapy
  subject:
    topic: Neoplasms
    topic: therapy
  subject:
    topic: Immunotherapy
  subject:
    topic: Molecular Targeted Therapy
  subject:
    topic: Cancer
    topic: Immunothérapie
  subject:
    topic: Immunothérapie
  subject:
    topic: Cancer
    topic: Treatment
    topic: Technological innovations
  classification: RC270.8 .T74 2023
  classification: 616.99/406
  related item:
    identifier: (OCoLC)1371139844
  related item:
    title info:
      title: Treatment Landscape of Targeted Therapies in Oncology
    name:
      name part: Maurya, Pawan Kumar
    origin info:
      publisher: San Diego : Elsevier Science & Technology,c2023
  identifier: 9780443160356
  identifier: 044316035X
  identifier: 9780443160349
  identifier: 0443160341
  identifier: http://proxy.library.tamu.edu/login
  record info:
    record content source: YDX
    record creation date: 230804
    record change date: 20260327174719.6
    record identifier: in00005771973
    language of cataloging:
      language term: eng